Scott Holmes, DO
Gastroenterology · Overland Park, KSNPI 1194003368
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 384 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 38.2% of the total.
Across 384 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$518
- Bristol Myers Squibb$481
- Pfizer$379
- Takeda Pharmaceuticals U.S.A., Inc.$251
- Merck$242
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,778100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 180 | $2,209 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 32 | $518 |
| Bristol Myers Squibb | 39 | $481 |
| Pfizer | 26 | $379 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $251 |
| Merck | 16 | $242 |
| Sanofi | 8 | $183 |
| Johnson & Johnson | 10 | $169 |
| Ardelyx, Inc. | 8 | $149 |
| Endogastric Solutions, Inc | 1 | $132 |
| Celltrion USA Inc. | 6 | $112 |
| Ferring Pharmaceuticals Inc. | 4 | $111 |
| E.r. Squibb & Sons, L.L.C. | 1 | $100 |
| Amgen | 4 | $89 |
| Braintree Laboratories, Inc. | 4 | $69 |
| Lilly USA, LLC | 2 | $66 |
| Intercept Pharmaceuticals, Inc. | 4 | $63 |
| Regeneron Healthcare Solutions, Inc. | 3 | $59 |
| QOL Medical, LLC | 3 | $57 |
| Olympus America Inc. | 1 | $55 |
| Gilead | 3 | $46 |
| Redhill Biopharma Inc. | 2 | $33 |
| Organon | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Nestle Healthcare Nutrition Inc. | 1 | $30 |
| Micro-tech Endoscopy USA, Inc. | 2 | $29 |
| Ironwood Pharmaceuticals, Inc | 2 | $28 |
| Mylan Institutional Inc. | 1 | $16 |
| Digestive Care, Inc. | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ESOPHYX$132
How this compares
$5,778 in reported general payments places this provider in the 80th percentile of 98 gastroenterology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 12 | $333,463 |
| LinzessLinaclotide | 18 | $9,327 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 107 | $7,039 |
| Colestipol Hcl | 60 | $4,266 |
| Omeprazole | 149 | $2,113 |
| Pantoprazole Sodium | 128 | $1,926 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 113 | $1,572 |
| Cholestyramine LightCholestyramine | 12 | $571 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 33 | $486 |
| Famotidine | 62 | $448 |
| Lansoprazole | 14 | $262 |
| Ondansetron OdtOndansetron | 11 | $193 |
| Dicyclomine Hcl | 15 | $159 |
| Ondansetron Hcl | 11 | $154 |
| Spironolactone | 13 | $33 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $169 | $333,46312 claims |
| AbbVieLinzess | $2,209 | $9,32718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 98 gastroenterology providers in Kansas.
Other gastroenterology in Overland Park
- Erica DaileyOverland Park$33K
- James AllenOverland Park$9K
- Matthew HarrisonOverland Park$7K
- Christian McElhinneyOverland Park$7K
- Rishi GrewalOverland Park$6K
- Donald MartinOverland Park$5K
- Jeffrey YoungOverland Park$3K
- Jon NicholsOverland Park$3K
- Richard SuttonOverland Park$2K
- Randal BrownOverland Park$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.